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Abstract: Topiramate is an oral sulphamate medication primarily used for seizure, migraine and neuropathic pain. It has 
been associated with secondary angle closure, which can mimic acute angle closure glaucoma. Suspicion for medication 
induced angle closure glaucoma should be higher whenever angle closure presents bilaterally. We present two cases of bi-
lateral angle closure glaucoma secondary to topiramate. 
  We present two cases of bilateral secondary angle closure 
glaucoma related to Topiramate which mimic primary acute 
angle closure glaucoma. The first case is a 48 year old fe-
male referred by an outside ophthalmologist for acute vision 
loss and elevated intraocular pressure. The patient initially 
noted a “fog” of her vision in both eyes and halos around 
lights. Soon after noticing these symptoms, she developed a 
bifrontal headache. Her past ocular history was significant 
for convergence insufficiency and visual difficulties after 
suffering a concussion during a motor vehicle accident in 
November 2003. Her medical history was notable for bipolar 
disorder, depression, hypothyroidism, and chronic pain sec-
ondary to cervical disc disease. Her medications included 
lithium, thiothixene, dicyclomine, mirtazapine, clonazepam, 
bupropion, atorvastatin, lexothyroxine, and she was recently 
on topiramate, 2 weeks prior, for pain control. Her family 
history was significant for cataracts and retinal detachment, 
but no glaucoma. 
  Her vision was 20/50 in each eye with correction. Pupils 
were both 7mm and sluggishly reactive without a relative 
afferent pupillary defect. Despite aggressive topical aqueous 
suppressants, pilocarpine and IV mannitol, intraocular pres-
sure (IOP) on arrival was 67 mmHg right eye and 78 mmHg 
left eye. Slit lamp exam revealed mild chemosis, injection 
and ciliary flush with diffuse stromal haze and very shallow 
peripheral anterior chambers with areas of iridocorneal touch 
in both eyes. Gonioscopy showed closed angles, and oph-
thalmoscopy revealed normal optic discs bilaterally, with 
healthy rim tissue and 0.2-0.3 cup to disc ratios in both eyes. 
Peripheral retinal exam and standard B-scan ultrasonography 
showed no apparent suprachoroidal effusion The  diagnosis 
of bilateral secondary acute angle closure glaucoma due to 
topiramate was made and the patient was managed with 
topical aqueous suppressants, oral hyperosmotics and dis-
continuing pilocarpine. Her intraocular pressure improved, 
but was not adequately controlled until cycloplegia was initi-
ated. Her pain management physician was notified and the 
topiramate was discontinued. Over the next week, the pa-
tient’s vision returned to 20/20 in each eye. Cycloplegic reti-
noscopy revealed -0.75 sphere right eye and -0.25 sphere left 
eye. Topical aqueous suppressants and cycloplegia were con-
tinued until intraocular pressure on day 8 was 15 mmHg left  
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eye and 16 mmHg right eye. The patient was instructed to 
taper her ocular medications and return to the care of her 
regular referring ophthalmologist. 
  Our second patient is a 53 year old Asian male who pre-
sented to our emergency room with severe headaches and 
vision loss. He had no ocular history and a past medical his-
tory significant only for cluster headaches and hyperlipide-
mia. Family history was not significant for ocular diseases. 
He had been complaining of right sided headaches and pho-
tophobia for the past 2 months, and was diagnosed with clus-
ter headaches by his primary care physician. He was under-
going oxygen therapy at home, and his medications included 
eletriptan, sumatriptan, atorvastatin and topiramate. His topi-
ramate was started 6 weeks ago by his primary care physi-
cian in an attempt to better control his headaches. A month 
prior to his presentation, he was evaluated by an optometrist 
who noted normal anterior structures and a normal IOP. On 
the night before his arrival to the emergency room, he woke 
up with severe headaches, photophobia and blurry vision in 
both eyes. On exam, his vision was 20/400 in both eyes, and 
his pupils were 6mm in both eyes and sluggishly reactive, 
without an appreciable relative afferent papillary defect. His 
IOP was 72 mmHg in the right eye and 68 mmHg in the left 
eye initially. He was given acetazolamide and timolol upon 
arrival by the emergency room, which did not significantly 
lower his pressure. Slit lamp exam revealed significant che-
mosis, mild injection and ciliary flush and very shallow pe-
ripheral anterior chambers with areas of iridocorneal touch in 
both eyes. Careful examination of the lens revealed glau-
comflecken. Gonioscopy showed closed angles, and oph-
thalmoscopy revealed normal optic discs bilaterally. B scan 
ultrasonography showed questionable suprachoroidal effu-
sions in both eyes. The cornea was initially clear, but pro-
gressively became more edematous during his course in the 
emergency room. Due to his poorly controlled IOP, he was 
started on multiple topical aqueous suppressants and IV 
mannitol, which lowered his IOP to 34 mmHg in the right 
eye and 37 mmHg in his left eye. The differential was bilat-
eral secondary angle closure glaucoma due to topiramate 
versus primary angle closure glaucoma, for which the treat-
ment is vastly different. The patient was started on pilo-
carpine so that he could undergo bilateral laser peripheral 
iridotomies (LPI). After undergoing bilateral LPIs, his IOP 
did not significantly change. He was then started on topical 
prednisolone for his anterior chamber inflammation and cy-
cloplegics, the recognized treatment for secondary angle 
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aqueous suppressants and oral acetazolamide. Pilocarpine 
was stopped and the patient was also told to discontinue his 
topiramate. His pressure gradually normalized over the next 
several days, his vision improved to 20/40 bilaterally. His 
topical aqueous suppressants were tapered as his IOP re-
mained stable. Gonioscopy after his IOP normalized re-
vealed bilateral open angles and several small bilateral pe-
ripheral anterior synechiae. 
  Topiramate, brand name Topamax, is an anticonvulsant 
drug that is used for seizure, migrane and neuropathic pain. 
It is a sulfamate-substituted monosaccharide. Other sulfa 
based drugs such as acetazolamide, hydrocholorothiazide 
and cotrimoxazole have been associated with secondary an-
gle closure glaucoma [1]. Topiramate was first implicated as 
a cause of bilateral acute angle closure glaucoma in a case 
report by Banta, et al. in July of 2001 [2]. A recent review of 
case reports of adverse effects of topiramate use revealed 
abnormal vision, acute secondary angle closure glaucoma, 
acute myopia and suprachoroidal effusions [3]. The proposed 
mechanism of myopia and secondary angle closure is chor-
oidal effusion and forward rotation of the iris-lens dia-
phragm. The effusion places pressure on the vitreous body 
and compresses the lens-iris diaphragm, causing anterior 
displacement and closure of the angle [4-8]. The treatment 
for topiramate induced secondary angle closure are cyclople-
gia and topical corticosteroids. Cycloplegia relaxes the cilary 
body and tighten the zonules, keeping the iris-lens dia-
phragm in check. 
  Topiramate use can cause an angle closure glaucoma that 
presents in a variety of forms and can mimic primary acute 
angle closure glaucoma. A careful inquiry of current and past 
medications is critical in the evaluation of angle closure 
glaucoma. Most cases of topiramate-associated angle-closure 
glaucoma present within the first 2 weeks of treatment but 
reactions have been reported within hours of the first dose or 
as long as seven weeks after onset of therapy. A recent case 
report revealed a patient who took topiramate three times one 
month prior to the onset of her symptoms, did not respond to 
LPI for acute angle closure glaucoma, and only then was 
diagnosed with topiramate associated secondary angle clo-
sure, illustrating the importance of a careful medication in-
quisition and the difficulty of differentiating primary versus 
secondary angle closure [9]. Our first patient presented with 
pupils which were reactive, serving as a clue that this patient 
did not have pupillary block, and yet did not have evidence 
of the classic suprachoriodal effusions which were expected 
to be seen on B-scan. In addition, our first patient was 
chronically taking dicyclomine, an anticholinergic medica-
tion, for irritable bowel syndrome which could predispose 
patients to angle closure glaucoma. However, given the re-
cent initiation of topiramate, and lack of response to standard 
treatment, it is unlikely that the patient’s glaucoma was at-
tributable to dicyclomine. Our second patient presented with 
evidence pointing towards both acute angle closure glau-
coma and topiramate induced secondary angle closure glau-
coma. He had sluggish mid dilated pupils and glaucom-
flecken, but also choroidal effusions on B-scan. His IOP did 
not respond to standard treatment for acute angle closure 
glaucoma, including LPI. He only improved after aggressive 
cycloplegia and topical steroids. When faced with an unusual 
presentation of bilateral angle closure glaucoma, with a his-
tory of topiramate use being elicited on history, it is reason-
able to initially treat the patient with bilateral LPIs and then 
topical corticosteroids and cycloplegics. 
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